Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Idenix May Drop Delayed Hepatitis C Drug for New Versions

Idenix Pharmaceuticals Inc., a developer of hepatitis C drugs, may shelve experimental treatments currently on hold by U.S. regulators and focus on different versions, Chief Executive Officer Ron Renaud said.

The Food and Drug Administration is continuing to assess trials halted last year on two drugs, Cambridge, Massachusetts-based Idenix said today in a slide presentation released ahead of the company’s appearance at the JPMorgan Chase & Co. health-care conference in San Francisco.

The FDA put a hold on studies of the company’s IDX184 and IDX19368 after safety issues arose while Bristol-Myers Squibb Co. tested a hepatitis C therapy in the same family of nucleotide compounds, called guanosines. Bristol-Myers, based in New York, ended development of its therapy Aug. 23 after it was linked to the death of one patient and kidney and heart concerns in others.

“We believe there are significant differences” between Idenix’s drugs and the Bristol-Myers treatment, Idenix said in the slides. The company expects a response from the FDA this quarter, according to the presentation.

Idenix is also developing different versions of nucleotides, called uridines, and plans proof-of-concept testing before July, Renaud said in the interview. At the same time, Idenix will test a therapy in a separate class of drugs, a so-called NS5A, with compounds from other companies, to gauge its effectiveness during a 12-week duration.


“We feel very good about our ability to combine the NS5A in the first half, get that data, and be on track for the fourth quarter to combine our own nuc with our own NS5A,” he said. “It’s a semi-reset.”

Idenix fell 5.9 percent to $4.76 at the close in New York, the time. Idenix shares have declined 51 percent over the 12 months.

Renaud said the company will need to hear more about the FDA’s concerns before going forward with the experimental drugs on hold -- IDX184 and IDX19368.

“We’ll have to make some business decisions,” Renaud said. “We have to see what conditions the FDA puts on them. We haven’t decided.

‘‘Quite simply, we’ve given all the information to the FDA, and the FDA just needs more time,” he said. “What we have to figure out is exactly the FDA’s concerns.”

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.